Table 1. Clinicopathological features of ovarian CCC patients with or without VTE.
| Variables | Cohort | VTE group | Non VTE group | P * |
|---|---|---|---|---|
| Number | 227(100%) | 33(14.5%) | 194(85.5%) | |
| Age (range) (years) | 50(29–81) | 51(31–73) | 49(29–81) | 0.379 |
| Serum CA 125 (Mean ± SD) (U/ml) | 811.5±1681.9 n = 197 | 960.6±2409.9 n = 25 | 789.7±1556.8 n = 172 | 0.734 |
| Stage Group | ||||
| Early (I+II) | 122(53.7%) | 10(30.3%) | 112(57.7%) | 0.003 |
| Advanced (III+IV) | 105(46.3%) | 23(69.7%) | 82(42.3%) | |
| Primary Tumor size (Mean ± SD) (range) (cm) | 10.9±5.11(1–30) n = 190 | 12.1±5.58(3–25) n = 28 | 10.6±5.01(1–30) n = 162 | 0.213 |
| Primary tumor size≥ 10cm | 98(51.6%) | 16(57.1%) | 82 (50.6%) | 0.523 |
| Ascites ≥0.5L | 51(22.5%) | 10(30.3%) | 41(21.1%) | 0.243 |
| Residual disease | ||||
| ≤1cm (optimal) | 153(67.4%) | 17(51.5%) | 136(70.1%) | 0.035 |
| >1cm (suboptimal) | 74(32.6%) | 16(48.5%) | 58(29.9%) | |
| Lymph node dissection | 196(86.3%) | 21(63.6%) | 175(90.2%) | <0.001 |
| Adjuvant chemotherapy | 219(96.4%) | 31(93.9%) | 188(96.9%) | 0.731 |
| Status | ||||
| Alive | 154(67.8%) | 12(36.4%) | 142(73.2%) | <0.001 |
| Dead | 73(32.2%) | 21(63.6%) | 52(26.8%) | |
*Chi-square test and parametric student t test.
Abbreviations: CCC, clear cell carcinoma; SD, standard deviation; VTE, venous thromboembolism; CA 125, cancer antigen 125.